Fadrozole

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Fadrozole
Fadrozole structure.svg
Clinical data
Trade names Afema
Routes of
administration
By mouth
Drug class Aromatase inhibitor; Antiestrogen
ATC code
  • None
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard 100.159.562
Chemical and physical data
Formula C14H13N3
Molar mass 223.27 g/mol
3D model (JSmol)
 NYesY (what is this?)  (verify)

Fadrozole (INN), sold under the brand name Afema (by Novartis), is a selective, nonsteroidal aromatase inhibitor which is or has been used in Japan for the treatment of breast cancer.[1][2]

References[edit]

  1. ^ Browne LJ, Gude C, Rodriguez H, Steele RE, Bhatnager A (February 1991). "Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease". J. Med. Chem. 34 (2): 725–36. doi:10.1021/jm00106a038. PMID 1825337. 
  2. ^ Raats JI, Falkson G, Falkson HC (January 1992). "A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer". J. Clin. Oncol. 10 (1): 111–6. doi:10.1200/jco.1992.10.1.111 (inactive 2017-02-11). PMID 1530798.